Bluebird Bio Inc. (NASDAQ:BLUE) rose 3.4% on Thursday . The stock traded as high as $57.71 and last traded at $57.29, with a volume of 431,729 shares. The stock had previously closed at $55.43.

BLUE has been the subject of several recent research reports. Wedbush reaffirmed an “outperform” rating and set a $117.00 price target on shares of Bluebird Bio in a report on Wednesday, August 3rd. Leerink Swann reissued a “buy” rating on shares of Bluebird Bio in a report on Monday, June 13th. Goldman Sachs Group Inc. reissued a “neutral” rating and issued a $149.00 target price on shares of Bluebird Bio in a report on Saturday, April 23rd. Janney Montgomery Scott reissued a “buy” rating and issued a $91.00 target price on shares of Bluebird Bio in a report on Tuesday, May 10th. Finally, Vetr downgraded Bluebird Bio from a “strong-buy” rating to a “sell” rating and set a $44.44 target price for the company. in a report on Wednesday, June 8th. Six analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $92.59.

The company has a 50 day moving average price of $52.01 and a 200-day moving average price of $46.81. The company’s market capitalization is $2.00 billion.

Bluebird Bio (NASDAQ:BLUE) last announced its quarterly earnings results on Wednesday, August 3rd. The company reported ($1.59) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.44) by $0.15. The business earned $1.55 million during the quarter, compared to the consensus estimate of $2.01 million. The business’s revenue for the quarter was down 68.6% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.57) EPS. On average, equities analysts expect that Bluebird Bio Inc. will post ($6.14) earnings per share for the current year.

In other Bluebird Bio news, insider Eric Sullivan sold 2,912 shares of the business’s stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of $55.01, for a total transaction of $160,189.12. Following the completion of the transaction, the insider now owns 4,456 shares in the company, valued at approximately $245,124.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider David Davidson sold 1,000 shares of the business’s stock in a transaction on Wednesday, June 15th. The stock was sold at an average price of $40.11, for a total value of $40,110.00. Following the transaction, the insider now owns 10,600 shares of the company’s stock, valued at approximately $425,166. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have made changes to their positions in the company. RS Investment Management Co. LLC raised its position in shares of Bluebird Bio by 91.6% in the fourth quarter. RS Investment Management Co. LLC now owns 515,846 shares of the company’s stock worth $33,128,000 after buying an additional 246,622 shares during the period. State of Tennessee Treasury Department raised its position in shares of Bluebird Bio by 45.4% in the fourth quarter. State of Tennessee Treasury Department now owns 191,963 shares of the company’s stock worth $12,328,000 after buying an additional 59,952 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Bluebird Bio by 6.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 74,831 shares of the company’s stock worth $4,806,000 after buying an additional 4,454 shares during the period. Finally, Jennison Associates LLC raised its position in shares of Bluebird Bio by 171.3% in the fourth quarter. Jennison Associates LLC now owns 864,314 shares of the company’s stock worth $55,506,000 after buying an additional 545,727 shares during the period.

bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.